Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib /II Trial of Pembrolizumab and Idelalisib in Patients With Non-small Cell Lung Cancer (NSCLC) Who Have Failed Immune Checkpoint Inhibitor

NCT03257722 is registered in ClinicalTrials.gov with Asha Nayak as lead sponsor.

NCT NCT03257722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03257722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib /II Trial of Pembrolizumab and Idelalisib in Patients With Non-small Cell Lung Cancer (NSCLC) Who Have Failed Immune Checkpoint Inhibitor
Lead sponsor
Asha Nayak
Phase
Phase 1/2
Overall status
Terminated
Start date
September 26, 2017
Completion date
August 25, 2021
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastasis, non small cell lung cancer, recurrence